Neoadjuvant chemotherapy with FOLFOX: Improved outcomes in Chinese patients with locally advanced gastric cancer

Journal of Surgical Oncology

Volumn 105, Issue 8, 2012, Pages 793-799

  Li, Zi Yu ^a   Koh, Cherry E ^b   Bu, Zhao De ^a   Wu, Ai Wen ^a   Zhang, Lian Hai ^a   Wu, Xiao Jiang ^a   Wu, Qi ^a   Zong, Xiang Long ^a   Ren, Hui ^a   Tang, Lei ^a   Zhang, Xiao Peng ^a   Li, Ji You ^a   Hu, Ying ^a   Shen, Lin ^a   Ji, Jia Fu ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

China; FOLFOX; gastric cancer; neoadjuvant chemotherapy; oxaliplatin; surgery

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHINESE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GASTRECTOMY; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; OVERALL SURVIVAL; PARESTHESIA; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; STOMACH CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEAKNESS;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84861098724     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23009     Document Type: Article

References (49)

1. Parkin DM, Ferlay J, Pisani P,: Global cancer statistics. CA Cancer J Clin 2005; 55: 74-108.
2. Alberts SR, van de Velde CJ,: Gastric cancer: Epidemiology, pathology and treatment. Ann Oncol 2003; 14: ii31-ii36. (Pubitemid 36874136)
3. Yang L,: Incidence and mortality of gastric cancer in China. World J Gastroenterol 2006; 12: 17-20. (Pubitemid 43126077)
4. Cunningham D,: East meets west in the treatment of gastric cancer. N Eng J Med 2007; 357: 1863.
5. Hansson LE,: Nyren O survival in stomach cancer is improving: Results of a nationwide population-based Swedish study. Ann Surg 1999; 230: 162-1169.
6. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach of gastroesophageal junction. N Eng J Med 2001; 345: 725-730.
7. Kim S, Lim DH, Lee J, et al.: An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005; 63: 1279-1285. (Pubitemid 41628018)
8. Wagner AD, Unverzagt S, Grothe W, et al.: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010; 3: CD004064.
9. Cunningham D, Stenning SP, Thompson JN,: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Eng J Med 2006; 355: 11-20.
10. Ajani JA, Ota DM, Jessup JM, et al.: Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer 1991; 68: 1501-1506.
11. Ajani JA, Mayer RJ, Ota DM, et al.: Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst 1993; 85: 1839-1844. (Pubitemid 23333617)
12. Songun I, Keizer HJ, Hermans J, et al.: Chemotherapy for operable gastric cancer: Results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Goup. (DGCG). Eur J Cancer 1999; 35: 558-562. (Pubitemid 29192962)
13. De Vita F, Orditura M, Matano E, et al.: A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 2005; 92: 1644-1649. (Pubitemid 40762627)
14. Luo HY, Xu RH, Zhang L, et al.: A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer. Chemotherapy 2008; 54: 228-235. (Pubitemid 351929275)
15. Wöhrer SS, Raderer M, Hejna M,: Palliative chemotherapy for advanced gastric cancer. Ann Oncol 2004; 15: 1585-1595. (Pubitemid 39567288)
16. Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al.: Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004; 22: 658-663. (Pubitemid 41102130)
17. Louvet C, André T, Tigaud JM, et al.: Phae II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002; 20: 4543-4548. (Pubitemid 35407422)
18. Hsu CH, Yeh KH, Chen LT, et al.: Weekly 24-hour infusion of high dose 5-flourouracil and leucovorin in the treatment of advanced gastric cancers. An effective and low toxix regimen for patients with poor general condition. Oncology 1997; 54: 275-280.
19. Cunningham J, Bukowski RM, Budd GT, et al.: Purvis J 5-fluorouracil and folinic acid: A phase I-II trial in gastrointestinal malignancy. Invest New Drugs 1984; 2: 391-395. (Pubitemid 15219440)
20. Raymond E, Faivre S, Woynarowski JM, et al.: Oxaliplatin: Mechanism of acion and antineoplastic activity. Semin Oncol 1998; 25: 4-12. (Pubitemid 28248696)
21. Bleiberg H, de Gramont A,: Oxaliplatin plus 5-fluouracil: Clinical experience in patients with advanced colorectal cancer. Semin Oncol 1998; 25: 32-39. (Pubitemid 28248699)
22. Raymond E, Chaney SG, Taamma A, et al.: Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 1998; 9: 1053-1071. (Pubitemid 28518143)
23. Caussanel JP, Lévi F, Brienza S, et al.: Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990; 82: 1046-1050. (Pubitemid 20204976)
24. World Health Organisation: WHO handbook for reporting results of cancer treatment. Available from:, 1979.
25. Miller AB, Hoogstraten B, Staquet M, et al.: Reporting results of cancer treatment. Cancer 1981; 47: 207-214. (Pubitemid 11167383)
26. Kajitani T,: The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J Surg 1981; 11: 127-139. (Pubitemid 11080134)
27. Nishi M, Omori Y, Miwa K, et al.: Japanese classification of gastric carcinoma, 1st English edition. Tokyo, Japan: Japanese Research Society for Gastric Cancer; 1995.
28. Lowy AM, Mansfield PF, Leach SD, et al.: Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999; 229: 303-308. (Pubitemid 30191763)
29. Newman E, Marcus SG, Potmesil M, et al.: Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally. J Gastrointest Surg 2002; 6: 212-223. (Pubitemid 40433574)
30. Preusser P, Wilke H, Achterrath W, et al.: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989; 7: 1310-1317. (Pubitemid 19220134)
31. Wilke H, Preusser P, Fink U, et al.: Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: A phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989; 7: 1318-1326. (Pubitemid 19220135)
32. Plukker JT, Mulder NH, Sleijfer DT, et al.: Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: Phase II study with methotrexate and 5-fluorouracil. Br J Surg 1991; 78: 955-958.
33. Fink U, Schuhmacher C, Stein HJ, et al.: Preoperative chemotherapy for stage III-V gastric carcinoma: Feasibility. Br J Surg 1995; 82: 1248-1252.
34. Kelsen D, Karpeh M, Schwartz G, et al.: Neoadjuvant therapy of high-risk gastric cancer: A phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J Clin Oncol 1996; 14: 1818-1828. (Pubitemid 26185457)
35. Crookes P, Leichman CG, Leichman L, et al.: Systemic chemotherapy for gastric carcinoma followed by postoperative. Cancer 1997; 79: 1767-1775.
36. Ajani JA, Mansfield PF, Lynch PM, et al.: Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 1999; 17: 2403-2411. (Pubitemid 29368239)
37. Gallardo RD, Onate Ocana LF, Calderillo RG,: Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: A phase II study. Ann Surg Oncol 2000; 7: 45-50.
38. Weese JL, Harbison SP, Stiller GD, et al.: Neoadjuvant chemotherapy, radical resection with intraoperative radiation therapy (IORT): Improved treatment for gastric adenocarcinoma. Surgery 2000; 128: 564-571.
39. National Comprehensive Cancer Network: Gastric Cancer (Including cancer in the proximal 5cm of stomach). NCCN Clinical Practice Guidelines in Oncology 2011 [cited 2011 24/10/2011];2:[Available from:.
40. Mackenzie M, Spithoff K, Jonker D,: Systemic therapy for advanced gastric cancer: A clinical practice guideline. Curr Oncol 2011; 18: 169-173.
41. Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al.: Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Cln Oncol 2004; 22: 658.
42. Lordick F, Lorenzen S, Stollfuss J, et al.: Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer 2005; 93: 190-194. (Pubitemid 41135888)
43. Webb A, Cunningham D, Scarffe JH, et al.: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267. (Pubitemid 27020582)
44. Ross P, Nicolson M, Cunningham D, et al.: Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20: 1996-2004. (Pubitemid 34413593)
45. Uncu D, Ozdemir NY, Aksoy S, et al.: Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and astroesophageal junction adenocarcinoma. Asian Pac J Cancer Prev 2010; 11: 1493-1497.
46. Orditura M, De Vita F, Muto P, et al.: Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: a pilot study. Arch Surg 2010; 145: 233-238.
47. Swisher SG, Holmes EC, Hunt KK, et al.: The role of neoadjuvant therapy in surgically resectable esophageal cancer. Arch Surg 1996; 131: 819-824 (discussion 824-825).
48. Sasako M, Sano T, Yamamoto S, et al.: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. New Engl J Med 2008; 359: 453-462.
49. Sakuramoto S, Sasako M, Yamaguchi T, et al.: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820. (Pubitemid 350044801)